Key result
Dabigatran achieves rapid anticoagulation with a ~1.4-minute equilibration half-time for activated clotting time.
Why the study?
Dabigatran has potential utility during cardiopulmonary bypass in children and adults, but its pharmacokinetic-pharmacodynamic relationship needed investigation in an intact animal model.
Does intravenous dabigatran have a predictable concentration-effect relationship for anticoagulation in a rabbit model?
Does intravenous dabigatran have a predictable concentration-effect relationship for anticoagulation in a rabbit model?
Intravenous dabigatran exhibits rapid onset and a predictable concentration-response for anticoagulation, supporting its potential investigation for use during cardiopulmonary bypass.
Answers are grounded in this paper and cite their sources.
Short equilibration supports rabbit PK/PD modeling; leaves open translation to human perioperative anticoagulation.
Introduction Dabigatran is an anticoagulant with potential use during cardiopulmonary bypass in children and adults. The pharmacokinetic–pharmacodynamic relationship for dabigatran anticoagulation effect was investigated in an intact animal model using rabbits. Methods Ten male New Zealand white rabbits were given a novel preparation of intravenous dabigatran 15 mg.kg −1 . Blood samples were collected for activated clotting time, thromboelastometric reaction time, and drug assay at 5, 15, 30, 60, 120, 180, 300, and 420 min. Plasma dabigatran concentrations and coagulation measures were analyzed using an integrated pharmacokinetic–pharmacodynamic model using nonlinear mixed effects. Effects (activated clotting and thromboelastometric reaction times) were described using a sigmoidal E MAX model. Pharmacokinetic parameters were scaled using allometry and standardized to a 70 kg size standard. Pharmacodynamics were investigated using both an effect compartment model and an indirect response (turnover) model. Results A two‐compartment model described dabigatran pharmacokinetics with a clearance (CL 0.135 L.min −1 .70 kg −1 ), intercompartment clearance (Q 0.33 L.min −1 .70 kg −1 ), central volume of distribution (V1 12.3 L.70 kg −1 ), and peripheral volume of distribution (V2 30.1 L.70 kg −1 ). The effect compartment model estimates for a sigmoid E MAX model with activated clotting time had an effect site concentration (Ce 50 20.1 mg.L −1 ) eliciting half of the maximal effect (E MAX 899 s) and a Hill coefficient (N 0.66). The equilibration half time (T 1/2 keo) was 1.4 min. Results for the reaction time were plasma concentration (Cp 50 65.3 mg.L −1 ), E MAX 34 min, N 0.80 with a baseline thromboelastometric reaction time of 0.4 min. The equilibration half time (T 1/2 keo) was 2.04 min. Conclusions Dabigatran reversibly binds to the active site on the thrombin molecule, preventing thrombin‐mediated activation of coagulation factors. The effect compartment model performed slightly better than the turnover model and was able to adequately capture pharmacodynamics for both activated clotting and thromboelastometric reaction times. The equilibration half time was short (<2 min). These data can be used to inform future animal preclinical studies for those undergoing cardiopulmonary bypass. These preclinical data also demonstrate the magnitude of parameter values for a delayed effect compartment model that are applicable to humans.
No takes yet. Share an insight, caveat, or question.
Eaton et al. (2022) studied this question. Dabigatran was evaluated on Pharmacokinetic-pharmacodynamic modeling of activated clotting time (ACT) and thromboelastometric reaction time. In a rabbit model, dabigatran pharmacodynamics for activated clotting time were captured by an effect compartment model, showing a short equilibration half-time of 1.4 minutes.
Synapse has enriched 10 related papers. Consider them for comparative context: